Krka Out Of The Blocks Solidly In Q1, With Russia Still Largest Market

Slovenian Firm ‘Second Largest Foreign Provider Of Generic Medicines’ In Russia

Krka has reaffirmed its full-year financial goals after a solid start to 2024, which included 8% revenue growth for its pharmaceutical products. Generics Bulletin examines the company’s sprawling global operations.

Russia
• Source: Shutterstock

Slovenian major Krka has enjoyed a solid start to 2024, welcoming 8% sales growth to €400.2m ($435m) for its prescription Pharmaceuticals segment in the first three months of the year and a group earnings before interest, tax, depreciation and amortization margin of 28.5%, “well above guidance.”

The Krka group’s largest region in terms of sales remained Eastern Europe, where overall revenues climbed by 9% to €156.4m...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business